Lucid Diagnostics, a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed, today announced the commencement of production of its EsoCheck Esophageal Cell Collection Devices at Coastline International, a high-volume manufacturer headquartered in San Diego with plants in Mexico.
The company has worked closely with Coastline over the past year to transfer the EsoCheck manufacturing lines from its prior low-volume manufacturer and to complete all the necessary validations to commence high-volume production at Coastline’s facility.
“The successful transition of EsoCheck production to a high-volume manufacturer reflects our deep commitment to drive efficiencies throughout the entire commercialization cycle,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “This transition will reduce the per-unit manufacturing cost of EsoCheck devices by approximately 60% and provide scalable manufacturing capacity to accommodate accelerating growth in EsoGuard Esophageal DNA Test testing volume. Following this transition, EsoCheck manufacturing capacity is now approximately 20,000 units per year. The system has been designed to allow capacity to be scaled to over one million units per year by adding additional manufacturing lines as demand dictates.”